OBJECTIVE: This study used gated myocardial perfusion imaging (G-MPI) to assess the clinical value of Xinmailong injection in chronic congestive heart failure (CHF). METHODS: A total of 102 CHF patients were randomly divided into the control group (n = 51) and the Xinmailong group (n = 51). Patients in the control group were routinely treated. Patients in the Xinmailong group were additionally treated with Xinmailong injection in addition to routine treatment. Before and 3 months after treatment, G-MPI was used to determine changes in the left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). Fourteen days after treatment, changes in plasma brain natriuretic peptide (BNP) levels were determined. RESULTS: Before treatment, there were no significant differences in LVEF, LVEDV, LVESV, and BNP levels between the two groups (all P > 0.05). After treatment, LVEDV, LVESV, and BNP levels were significantly lower, and LVEF was significantly higher in the Xinmailong group than in the control group (all P < 0.05). CONCLUSION: Additional use of Xinmailong injection in addition to routine treatment improves cardiac function of CHF patients. Because of the safety and effectiveness of Xinmailong injection; this therapy should be promoted.
RCT Entities:
OBJECTIVE: This study used gated myocardial perfusion imaging (G-MPI) to assess the clinical value of Xinmailong injection in chronic congestive heart failure (CHF). METHODS: A total of 102 CHFpatients were randomly divided into the control group (n = 51) and the Xinmailong group (n = 51). Patients in the control group were routinely treated. Patients in the Xinmailong group were additionally treated with Xinmailong injection in addition to routine treatment. Before and 3 months after treatment, G-MPI was used to determine changes in the left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). Fourteen days after treatment, changes in plasma brain natriuretic peptide (BNP) levels were determined. RESULTS: Before treatment, there were no significant differences in LVEF, LVEDV, LVESV, and BNP levels between the two groups (all P > 0.05). After treatment, LVEDV, LVESV, and BNP levels were significantly lower, and LVEF was significantly higher in the Xinmailong group than in the control group (all P < 0.05). CONCLUSION: Additional use of Xinmailong injection in addition to routine treatment improves cardiac function of CHFpatients. Because of the safety and effectiveness of Xinmailong injection; this therapy should be promoted.